Gene Patent Myths
Gene Patents and the Myriad patent case reveal the confusion that often occurs when you mix science, law, politics, and emotion. This article provides a digest of a series of blog posts on Biotech-Now that address common myths in the gene patent debate.
For more relevant facts read ‘Gene Patents’ are not necessary for health care innovation. Myth 3: ‘Gene Patents’ Stifle Research?
1. The Federal Trade Commission has concluded that concerns that strong biotechnology patent protection would obstruct commercialization have yet to materialize. Indeed, the FTC recently concluded that concern that patenting upstream technology, or “research tools,” would actually obstruct commercialization of new products and hinder follow-on innovation in biotechnology “has yet to materialize.”
2. In 2007, David Adelman from the University of Arizona and Kathryn DeAngelis from Piper Rudnick published a detailed study of more than 52,000 biotechnology patents found “few tangible signs of patent thickets that define the anti-commons.”
I agree with them. I don’t know well. I have specific information. But, It is necessary to technic.